Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis

Acta Neurologica Scandinavica

Volumn 110, Issue 6, 2004, Pages 386-392

  Bitsch, Andreas ^a   Bahner, D ^b   Wachter, C ^c   Elitok, E ^c   Bogumil, T ^d   Dressel, A ^e   Polak, T ^f   Tumani, H ^g   Weber, F ^h   Poser, S ^c   Kitze, B ^c  

^a Ruppiner Kliniken GmbH   (Germany)

^b KLINIKUM FULDA   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Specialized Therapeutics   (United States)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f KLINIKUM KASSEL   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adhesion molecules; Interferon beta 1b; Primary progressive multiple sclerosis; sE selectin; sVCAM 1

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM; FEMALE; FLU LIKE SYNDROME; HUMAN; INFECTION; MALE; MULTIPLE SCLEROSIS; PHARMACODYNAMICS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CELL ADHESION; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 8844263006     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00347.x     Document Type: Article

References (35)

1. BEVILACQUA MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804.
2. WASHINGTON R, BURTON J, TODD RF, NEWMAN W, DRAGOVIC L, DORE DUY P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97.
3. HARTUNG HP, REINERS K, ARCHELOS JJ et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-93.
4. RIECKMANN P, MICHEL U, ALBRECHT M, BRÜCK W, WOCKEL L, FELGENHAUER K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995;60:9-15.
5. TSUKADA N, MIVAGI K, MATSUDA M, YANAGISAWA N. Soluble E-selectin in the serum and cerebrospinal fluid of patients with multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Neurology 1995;45:1914-18.
6. DORE-DUFFY P, NEWMAN W, BALABANOV R et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62.
7. MATSUDA M, TSUKADA N, MIYAGI K, YANAGISAWA N. Increased levels of soluble vascular cell adhesion molecule-1 I (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 1995;59:35-40.
8. MCDONNELL GV, MCMILLAN SA, DOUGLAS JP, DROOGAN AG, HAWKINS SA. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. J Neurol 1999;246:87-92.
9. GIOVANNONI G, THORPE JW, KIDD D et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996;60:20-6.
10. ELOVAARA I, UKKONEN M, LEPPAKYNNAS M et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 2000;57:546-51.
11. CALABRESI PA, TRANQUILL LR, DAMBROSIA JM et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-74.
12. RIECKMANN P, ALTENHOFEN B, RIEGEL A, KALLMANN B, FELGENHAUER K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Mult Scler 1998;4:178-82.
13. THOMPSON AJ, POLMAN CH, MILLER DH et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-96.
14. MCDONNELL GV, HAWKINS FRCP. Application of the Poser criteria in primary progressive multiple sclerosis. Ann Neurol 1997;42:982-83.
15. MCDONALD WI, COMPSTON A, EDAN G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
16. KURTZKE JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1422-27.
17. NASH MC, WADE AM, SHAH V, DILLON MJ. Normal levels of soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease with age. Clin Exp Immunol 1996;103:167-70.
18. PUNGOR EJ, FILES JG, GABE JD et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998;18:1025-30.
19. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled study. Neurology 1993;43:655-61.
20. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-97.
21. BECHER B, GIACOMINI PS, PELLETIER D, MCCREA E, PRAT A, ANTEL JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999;45:247-50.
22. BONGIOANNI P, MOSTI S, MOSCATO G, LOMBARDO F, MANILDO C, MEUCCI G. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis. Arch Neurol 1999;56:71-8.
23. BONGIOANNI P, LOMBARDO F, MOSCATO G, MOSTI S, MEUCCI G. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis. Arch Neurol 1999;56:217-22.
24. KALLMANN BA, HUMMEL V, LINDENLAUB T, RUPRECHT K, TOYKA KV, RIECKMANN P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000;123:687-97.
25. CALABRESI PA, PELFREY CM, TRANQUILL LR, MALONI H, MCFARLAND HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-16.
26. MURARO PA, LEIST T, BIELEKOVA B, McFARLAND HF. VLA-4/ CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000;111:186-94.
27. DROOGAN AG, CROCKARD AD, MCMILLAN SA, HAWKINS SA. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology 1998;50:224-9.
28. GIOVANNONI G, LAI M, THORPE J et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-65.
29. DURAN I, MARTINEZ-CACERES EM, RIO J, BARBERA N, MARZO ME, MONTALBAN X. Immunological profile of patients with primary progressive multiple sclerosis: Expression of adhesion molecules. Brain 1999;122:2297-307.
30. POLMAN C, KAPPOS L, WHITE R et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37-43.
31. DAYAL AS, JENSEN MA, LLEDO A, ARNASON BG. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-77.
32. LOBB RR, CHI-ROSSO G, LEONE DR et al. Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1. J Immunol 1991;147:124-9.
33. PIGOTT R, DILLON LP, HEMINGWAY IH, GEARING AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992;187:584-9.
34. GEARING AJ, HEMINGWAY I, PIGOTT R, HUGHES J, REES AJ, CASHMAN SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci 1992;667:324-31.
35. LEARY SM, MILLER DH, STEVENSON VL, BREX PA, CHARD DT, THOMPSON AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51.